For US Healthcare Professionals Only
For US Healthcare Professionals Only
Most Frequent Adverse Reactions (Occurring in ≥10% of Patients) up to Week 24 (Cycle 7, Day 1)1,a
aSafety data from the Jakafi Prescribing Information.
bNational Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 4.03.1
Selected Laboratory Abnormalities up to Week 24 (Cycle 7, Day 1)1,a,b
aSafety data from the Jakafi Prescribing Information.
bPresented values are worst-grade values regardless of baseline.1
cNational Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 4.03.1
REACH3 Infections up to Week 24 (Cycle 7, Day 1)2,a
aSafety population: all patients who received ≥1 dose of study treatment.2
bInfections were classified by type at the investigator’s discretion by using an infection-specific grading system predictive of mortality that was developed for and validated in allogeneic stem cell transplant recipients based on the criteria provided in the protocol.2
ALT=alanine transaminase; AST=aspartate transaminase; BAT=best available therapy; REACH=Ruxolitinib in patiEnts with refrACtory graft-versus-Host disease after allogeneic stem cell transplantation.
References: 1. Jakafi [package insert]. Wilmington, DE: lncyte Corporation. 2. Zeiser R, Polverelli N, Ram R, et al; for the REACH3 Investigators. Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. N Engl J Med. 2021;385(3):228-238. Supplementary appendix available at: https://www.nejm.org/doi/full/10.1056/NEJMoa2033122.
Indications and Usage
Jakafi® (ruxolitinib) is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.
Jakafi is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.
Jakafi is indicated for treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older.
Jakafi is indicated for treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
Important Safety Information
Please see Full Prescribing Information for Jakafi.
Indications and Usage
Jakafi® (ruxolitinib) is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.
Jakafi is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.
Jakafi is indicated for treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older.
Jakafi is indicated for treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
Important Safety Information
Please see Full Prescribing Information for Jakafi.